SCHEMBL1853375

SCHEMBL1853375

O=C1CCC(=O)N1c1cccc(-c2cccc3cc(Cc4cccc(C(F)(F)F)c4)oc23)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 9/20 0.57
DPP4 P27487 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PARP1 P09874 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
DAO P14920 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3213465 0.79 GPR52 (0.62) GPR52CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1849964 0.78 GPR52 (0.75) GPR52MEN1KMT2AALDH1A1KDM4E
SCHEMBL1852519 0.74 GPR52 (0.68) GPR52MEN1KMT2AALDH1A1KDM4E
SCHEMBL1851771 0.73 GPR52 (1.00) GPR52
SCHEMBL1853223 0.72 GPR52 (0.61) GPR52MEN1KMT2AALDH1A1LMNA
SCHEMBL3209952 0.72 GPR52 (0.76) GPR52ALDH1A1NPSR1
SCHEMBL3215625 0.72 GPR52 (0.65) GPR52MEN1KMT2AALDH1A1KDM4E
SCHEMBL1847848 0.71 GPR52 (0.51) GPR52CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL3206803 0.70 GPR52 (0.81) GPR52ALDH1A1POLB
SCHEMBL1846506 0.70 GPR52 (0.81) GPR52ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885DPP4 3667/4885MEN1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.